Enlivex Ltd. is a clinical-stage biotech focused on macrophage reprogramming immunotherapy, primarily developing its lead product Allocetra™ using licensed apoptotic cell technology. The company holds an extensive intellectual property portfolio and outsources clinical trials, with no internal sales force, seeking partnerships for commercialization. Despite posting a significant net income gain in 2025 due to non-operating factors, operating losses and negative cash flows highlight ongoing funding needs as clinical development progresses. Key challenges include regulatory approvals, manufacturing scalability, and reimbursement dynamics across jurisdictions.